Robbie Stephens Boosts Human Genome

Analyst Michael King likes the company's strong fundamentals, drug pipeline and upcoming rights to a genomic database

Robertson Stephens upgraded Human Genome (HGSI )to strong buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.